

04 - 19 - 00

A

jc714 U.S. PTO  
04/18/00Please type a plus sign (+) inside this box → ☐PTO/SB/05 (4/98)  
Approved for use through 09/30/2000. OMB 0651-0032  
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE  
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.**UTILITY  
PATENT APPLICATION  
TRANSMITTAL**

(Only for new nonprovisional applications under 37 C.F.R. § 1.53(b))

Attorney Docket No.	IN01023K
First Inventor or Application Identifier	Brass, et al
Title	HCV COMBINATION THERAPY
Express Mail Label No.	EL226883706US

**APPLICATION ELEMENTS**

See MPEP chapter 600 concerning utility patent application contents.

1. ☒ \* Fee Transmittal Form (e.g., PTO/SB/17)  
(Submit an original and a duplicate for fee processing)
2. ☒ Specification [Total Pages 41]  
(preferred arrangement set forth below)
  - Descriptive title of the invention
  - Cross References to Related Applications
  - Statement Regarding Fed sponsored R & D
  - Reference to Microfiche Appendix
  - Background of the invention
  - Brief Summary of the invention
  - Brief Description of the Drawings (if filed)
  - Detailed Description
  - Claim(s)
  - Abstract of the Disclosure
3. ☐ Drawing(s) (35 U.S.C. 113) [Total Sheets ☐
4. Oath or Declaration [Total Pages ☐]
  - a. ☐ Newly executed (original or copy)
  - b. ☐ Copy from a prior application (37 C.F.R. § 1.63(d))  
(for continuation/divisional with Box 16 completed)
    - i. ☐ DELETION OF INVENTOR(S)  
Signed statement attached deleting inventor(s) named in the prior application, see 37 C.F.R. §§ 1.63(d)(2) and 1.33(b).

\* NOTE FOR ITEMS 1 & 13: IN ORDER TO BE ENTITLED TO PAY SMALL ENTITY FEES, A SMALL ENTITY STATEMENT IS REQUIRED (37 C.F.R. § 1.27), EXCEPT IF ONE FILED IN A PRIOR APPLICATION IS RELIED UPON (37 C.F.R. § 1.28).

**ADDRESS TO:** Assistant Commissioner for Patents  
Box Patent Application  
Washington, DC 20231

5. ☐ Microfiche Computer Program (Appendix)
6. Nucleotide and/or Amino Acid Sequence Submission (if applicable, all necessary)
  - a. ☐ Computer Readable Copy
  - b. ☐ Paper Copy (identical to computer copy)
  - c. ☐ Statement verifying identity of above copies

**ACCOMPANYING APPLICATION PARTS**

7. ☐ Assignment Papers (cover sheet & document(s))
8. ☐ 37 C.F.R. § 3.73(b) Statement of Power of Attorney (when there is an assignee)
9. ☐ English Translation Document (if applicable)
10. ☐ Information Disclosure Statement (IDS) (PTO-1449) [Copies of IDS Citations ☐
11. ☐ Preliminary Amendment
12. ☒ Return Receipt Postcard (MPEP 503)  
(Should be specifically itemized)
13. ☐ \* Small Entity Statement(s) filed in prior application, Status still proper and desired (PTO/SB/09-12)
14. ☐ Certified Copy of Priority Document(s) (if foreign priority is claimed)
15. ☒ Other: Unexecuted Declaration (4 pgs)  
Cover Sheet (1 pg)

**16. If a CONTINUING APPLICATION, check appropriate box, and supply the requisite information below and in a preliminary amendment:**
☐ Continuation ☐ Divisional ☐ Continuation-in-part (CIP) of prior application No: 60/129,991 / 4/19/99  
Prior application information: Examiner \_\_\_\_\_ Group / Art Unit: \_\_\_\_\_

**For CONTINUATION or DIVISIONAL APPS only:** The entire disclosure of the prior application, from which an oath or declaration is supplied under Box 4b, is considered a part of the disclosure of the accompanying continuation or divisional application and is hereby incorporated by reference. The incorporation can only be relied upon when a portion has been inadvertently omitted from the submitted application parts.

**17. CORRESPONDENCE ADDRESS**
☐ Customer Number or Bar Code Label (Insert Customer No. or Attach bar code label here) or ☒ Correspondence address below

Name	THOMAS D. HOFFMAN				
	Patent Dept. K-6-1, 1990				
Address	Schering-Plough Corporation				
	2000 Galloping Hill Road				
City	Kenilworth	State	New Jersey	Zip Code	07033-0530
Country	USA	Telephone	(908) 298-5037	Fax	(908) 298-5388

Name (Print/Type)	THOMAS D. HOFFMAN	Registration No. (Attorney/Agent)	28221
Signature	Thomas D Hoffman	Date	4/18/2000

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Box Patent Application, Washington, DC 20231.

 jc564 U.S. PTO  
09/551341  
04/18/00

**PATENT APPLICATION**  
**HCV COMBINATION THERAPY**

**INVENTORS:**

CLIFFORD A. BRASS, a citizen of the United States, residing at 19 Travelers Way, Scotch Plains, New Jersey 07076, USA.

PAUL W. GLUE, a citizen of New Zealand, residing at 13 Allens Corner Road, Flemington, New Jersey 08822, USA.

EDWARD PIKEN, a citizen of the United States, residing at 2007 Via Visalia, Palos Verdes Estates, California 90274, USA.

**ASSIGNEE:**

Schering Corporation

Express Mail No. EL226883706US  
Date of Deposit: April 18, 2000

THOMAS D. HOFFMAN  
Schering-Plough Corporation  
Patent Department, K-6-1, 1990  
2000 Galloping Hill Road  
Kenilworth, New Jersey 07033-0530  
Telephone: (908) 298-5037  
Fax: (908) 298-5388

## HCV COMBINATION THERAPY

### BACKGROUND OF THE INVENTION

The present invention relates to methods of treating patients having susceptible viral infections, especially chronic hepatitis C infections by administering to said patient a therapeutically effective amount of a combination therapy of interferon-alfa and ribavirin for a time sufficient to lower HCV-RNA in association with a therapeutically effective amount of an antioxidant for a time sufficient to ameliorate ribavirin-related hemolysis.

A chronic hepatitis C viral infection is a particularly insidious and slow-progressing viral disease having a significant impact on the quality of life. It can eventually result in cirrhosis of the liver, decompensated liver disease and/or hepatocellular carcinoma.

Combination treatment with interferon alfa-2b and ribavirin for chronic hepatitis C in patients. is disclosed by Reichard et al.(The Lancet **1998**; 351;83-87. T. Poynard et al.( The Lancet ,**1998**, Vol. 352, Oct. 31, p 1426-1432) disclose that treating chronic hepatitis C patients who had not been treated with interferon or ribavirin with 3 MIU of interferon alfa-2b TIW plus 1000-1200 mg of ribavirin per day for 48 weeks resulted in a sustained virological response at 24 weeks after treatment in 43% of the patients. See also J. G. McHutchinson et al. (N. Engl. J. Med.,**1998**, 339:1485-1492), G. L. Davis et al. (N. Engl. J. Med., **1998**, 339:1493-1499) disclose that treating chronic hepatitis C patients who relapsed after treatment with interferon with 3 MIU of interferon alfa-2b TIW plus 100-1200 mg of ribavirin per day for 48 weeks results in higher rates of sustained virologic response than treatment with interferon alone.

However this combination therapy is not always effective due to side effects associated ribavirin such as ribavirin-related hemolysis as measured by reduced hemoglobin concentrations. Both McHutchinson, et al and Poynard, et al

report that the majority of patients who completed the combination therapy had reached their lowest hemoglobin concentration by the fourth week of combination therapy at which time the hemoglobin concentrations either stabilized or increased. Ribavirin dose reduction to 600 mg/day was reported by  
5 McHutchinson, et al for patients with hemoglobin concentrations below 10 g per deciliter and treatment with ribavirin was discontinued in patients with hemoglobin concentration below 8.5 g per deciliter.

10 There is a need to provide an improved combination therapy for treating susceptible viral infections, especially chronic hepatitis C patients, to ameliorate the ribavirin-related hemolysis throughout the duration of the combination especially in the first 4 to 12 weeks, of therapy so as to produce a sustained virological response in more patients than previously possible.

### 15 SUMMARY OF THE INVENTION

The present invention provides methods for treating susceptible viral infections, especially hepatitis C viral infections, which comprises administering to said patient a therapeutically effective amount of ribavirin for a time sufficient to  
20 lower viral-RNA in association with a therapeutically effective amount of an antioxidant for a time sufficient to ameliorate ribavirin-related hemolysis.

The present invention provides a method of treating a patient having chronic HCV infection which comprises administering to said patient a  
25 therapeutically effective amount of a combination therapy of interferon-alfa and ribavirin for a time sufficient to lower HCV-RNA in association with a therapeutically effective amount of an antioxidant for a time sufficient to ameliorate ribavirin-related hemolysis.

30 The present invention provides a method of treating a patient having a chronic HCV infection which comprises administering to said patient for a first time period of at least about 24 weeks a therapeutically effective amount of a

combination therapy of interferon alfa and ribavirin sufficient to lower detectable HCV-RNA in association with a therapeutically effective amount of an antioxidant sufficient to ameliorate ribavirin-related hemolysis. In a preferred embodiment, the therapeutically effective amount of the combination therapy of interferon alfa and ribavirin is administered in a first time period of about 24 weeks for patients with HCV genotype 2 or 3, or in a first time period of about 48 weeks for patients with HCV genotype 1.

The present invention also provides a method of treating a patient having a chronic HCV infection which comprises (a) administering to said patient for a first time period a therapeutically effective amount of a combination therapy of interferon alfa and ribavirin sufficient to lower detectable HCV-RNA in association with a therapeutically effective amount of an antioxidant sufficient to ameliorate ribavirin-related hemolysis and (b) thereafter administering about 600 to about 1600 mg/day of ribavirin in association with the antioxidant for a second time period of at least about 24 weeks after the end of the first time period. In another preferred embodiment, the therapeutically effective amount of a combination therapy of interferon alfa and ribavirin is administered in a first time period of at least about 24 weeks, more preferably at least about 48 weeks.

The preferred interferon-alfa is interferon-alfa-2a or interferon-alfa-2b; use of interferon-alfa-2b is more preferred.

In a preferred embodiment, the present invention relates to a method of treating patients having chronic hepatitis C infection to eradicate detectable HCV-RNA comprising (a) administering to said patient, in a first treatment time period of twenty-four weeks, a therapeutically effective amount of an antioxidant sufficient to ameliorate ribavirin-related hemolysis in association with a combination of about 800 to 1200 mg per day of ribavirin and a therapeutically effective amount of interferon-alfa-2b in accordance with the following regimen: about 10 MIU daily of interferon-alfa-2b for two weeks, followed by 5 MIU daily of

interferon-alfa for six weeks, followed by 3 MIU daily of interferon-alfa  
 interferon-alfa for sixteen weeks, followed by (c) administering in a second treatment time  
 period of twenty-four weeks about 800 to 1200 mg per day of ribavirin and 3 MIU  
 TIW of interferon-alfa in association, a therapeutically effective amount of an  
 5 antioxidant sufficient to ameliorate ribavirin-related hemolysis.

The preferred antioxidants are Vitamin E derivatives including, but not  
 limited to, d-alpha-tocopherol and esters thereof, for example, the water soluble  
 d-alpha-tocopheryl polyethylene glycol esters such as the water dispersible  
 10 Vitamin E d-alpha-tocopheryl polyethylene glycol 1000 succinate ("Vitamin E-  
 TPGS") as well as use of compositions of Vitamin E-TPGS and at least one fatty  
 acid ester of glycerine having an overall melting point of 40°C (both of which are  
 disclosed in U.S. Patent 5,234,695 and available from Eastman Kodak Co.,  
 Rochester, NY).

#### 15 **DETAILED DESCRIPTION**

The present invention provides methods for treating susceptible viral  
 infections, especially hepatitis C viral infections.

The term "susceptible viral infections" as used herein means viral  
 20 infections caused by a wide range of RNA and DNA viruses, including, but not  
 limited to, the families of viruses such as flaviruses-including the genus flavirus,  
 pestivirus of which Kunjin virus is a member, and heparivirus of which hepatitis C  
 virus is a member, and arbovirus of which the West Nile virus is a member-  
 orthomyxoviruses, paramyxoviruses, arenaviruses, bunyaviruses, herpes viruses,  
 25 adenoviruses, poxviruses, and retroviruses.

Typical suitable "susceptible viral infections" include influenza A and B viral  
 infections; parainfluenza viral infections, respiratory syncytial virus ("RSV")  
 infections such as RSV bronchiolitis and RSV pneumonia especially such RSV  
 30 infections in children and infants as well as RSV pneumonia in patients with  
 preexisting cardiopulmonary disease, measles viral infections, Lassa fever viral  
 infections, Korean Haemorrhagic fever infections, hepatitis B viral (HBV)  
 infections, Crimean-Congo-Haemorrhagic and HCV infections and HIV-1  
 infections, encephalitis infections such as caused by West Nile virus or Kunjin

virus or the St. Louis encephalitis infections as well as viral infections found in immunocompromised patients. Other susceptible viral infections are disclosed in USP 4,211,771 at column 2, line 21 to column 3 line 37; doses and dose regimens and formulations are disclosed at column 3, line 4 to column 9, line 5; see also Canadian Patent No. 1,261, 265. Sidwell, R.W., et al. Pharmacol. Ther., 1979, Vol 6 pp 123-146 discloses that the in vivo antiviral experiments conducted with ribavirin generally confirm one broad-spectrum antiviral activity seen in vitro and states that the efficacy of ribavirin is quite dependent upon the site of infection; the manner of treatment; the age of the animal and the virus dosage utilized. Tables 4 and 5 on page 127 list the RNA and DNA virus infections significantly inhibited in vivo by ribavirin.

In a preferred embodiment, the present invention provides an improved method of treating patients having hepatitis C infection by allowing such patients to continue using the therapeutically effective amount of combination therapy of interferon alfa-2b and ribavirin such as approved by the FDA as well as other interferon alfa and ribavirin therapies under clinical development, e.g., pegylated interferon alfa 2a or 2b and ribavirin or described hereinafter. In a pilot study, twelve treatment-naive patients having chronic hepatitis C who received over the counter preparations of the antioxidants vitamin C (1000 mg/day) and vitamin E (800 IU/day) in combination with the FDA-approved combination therapy of 1000/1200 mg of ribavirin in two divided doses daily (1000 mg if body weight <75kg) and interferon alfa-2b, 3MIU SC TIW were able to continue for four months of the study without having to reduce the ribavirin dose. A control group of fourteen matched relapse patients having chronic hepatitis C received 1000mg of ribavirin in two divided doses daily and interferon alfa-2b, 3MIU SC TIW. Hemoglobin levels("HgB") were measured before treatment and at the end of weeks 2, 4, 8 and 12. Baseline HgB values of  $14.5 \pm 1.7$  and  $15.2 \pm 1.2$  in grams per deciliter("g/dl") were measured for the treatment-naive and relapse patients, respectively. Hemoglobin drops of 0.9, 1.7, 2.3 and 2.7 g/dl were measured in the treatment-naive patients at the end of weeks 2, 4, 8 and 12, respectively. Hemoglobin drops of 2.0, 3.0, 3.0 and 3.1 g/dl were measured in the relapse patients(control). The use of antioxidants in association with the combination therapy in accordance with the present invention markedly lowered the severity

of the ribavirin-related hemolytic anemia in the first twelve weeks of the combination therapy compared to historical controls and the relapse patients in the same pilot study. It was noteworthy that no patients receiving the antioxidants needed to reduce the ribavirin dose. However, three of the control patients  
5 required rivavirin dose reduction.

The patients treated in accordance with the preferred embodiments should have no detectable HCV-RNA at the end of said 48 week treatment period, also should have no detectable HCV-RNA for at least 24 weeks after the  
10 end of said 48 week period.

The present method of treating patients having chronic hepatitis C infections allows delivery of therapeutically effective amount of the combination of ribavirin and of interferon-alfa sufficient to substantially lower detectable HCV-  
15 RNA serum levels, preferably by at least two powers of ten, i.e., at least  $10^2$  lower than the initial HCV-RNA serum level, and more preferably eradicate detectable HCV-RNA serum levels. i.e., lower them to less than 100 copies/mL while simultaneously ameliorating the ribavirin-related hemolysis..

20 The term "antioxidant" as used herein means a substance that delays or inhibits hemolysis related to or promoted by administration of ribavirin.

The term "a therapeutically effective amount of an antioxidant" as used herein means an amount of antioxidant in the range of about one to about two  
25 hundred and fifty times, preferably about one to about two hundred times, more preferably ten to about one hundred times, most preferably ten to about fifty times the recommended daily dietary allowance ("RDA") of antioxidants (or the recommended daily amount if no RDA is reported for an antioxidant) useful in the methods of the present invention. The antioxidants useful in the methods of the  
30 present invention will normally be administered as long as the ribavirin is administered as part of the combination therapy, induction dosing and ribavirin



monotherapy delivered to the patient having susceptible viral infections , especially hepatitis C infections.

The term "in association with" as used herein in reference to administration of ribavirin monotherapy or the combination therapy of interferon-alfa and ribavirin with an antioxidant means that the antioxidant is administered prior to, concurrently with, or after administration of the combination therapy. The antioxidant may be administered orally, parenterally (e.g. IM, IP, SC or IV) or topically, e.g. by suppository. Oral or parenteral (e.g. subcutaneous) administration is preferred. Oral administration is more preferred. Typically, the antioxidant is administered in single or divided doses concurrently with the ribavirin which may be administered in single or divided doses BID.

Typically, suitable antioxidants include Vitamin A, Vitamin E, Vitamin C, silybum marianum, co-enzyme-Q10, BHA, BHT, N-acetylcysteine, selenium, panavir, lycopene, or mixtures thereof.

Vitamin A is described in Merck Index 11th Edition #9918 (and 4919) at pages 1576-77. The RDA is in the range of about 250 International Units ("IU")/day up to about 2500 IU/day; preferably about 2500 IU/day for newborns and infants.

The term "Vitamin E" as used herein includes all forms of tocopherol including, but not limited to, the naturally occurring and synthetic homologues of the four types of tocopherols (alpha-, beta-, gamma- and delta-tocopherol) and four types of tocotrienols, including esters thereof, e.g., alpha tocopheryl acetate or alpha tocopheryl succinate as well as the dextrorotatory ("d "), levorotatory ("l") optical isomers or mixtures of the d and l isomers. The d optical isomers are more active than l isomers and use of the optical isomers of vitamin E is preferred. The effective amount of Vitamin E useful in the present invention is in the range of one to two hundred and fifty (250) times, preferably one to one hundred times the recommended daily dietary allowance ("RDDA") of 3 to 10

alpha tocopherol equivalents per day; i.e., 3- 10 mg of d-alpha tocopherol per day. The activity of 1 mg of d-alpha tocopherol is equal to 1 alpha tocopherol equivalents. Since 1 mg of d-alpha tocopherol is equivalent to 1.49 International units (IU) of Vitamin E, about 4.5 to about 15 IU of Vitamin E is the RDDA. The activity of the following Vitamin E derivatives has been measured: one IU of Vitamin E is equivalent to 1 mg of dl-alpha tocopheryl acetate, 1 mg of d-alpha tocopheryl acetate has the potency of 1.36 IU of Vitamin E, 1 mg of d-alpha tocopherol has the potency of 1.49 IU of Vitamin E; and 1 mg of d-alpha tocopheryl succinate has the potency of 1.21 IU of Vitamin E;. See Goodman & Gilman's The Pharmacological Basis of Therapeutics, Ninth Edition, 1996, McGraw-Hill, pages 1549 and 1585-1590.

Suitable Vitamin E derivatives include d-alpha-tocopherol (available from Roche, Nutley, N.J. with a recommended daily allowance, of 10-30 mg per day equal to 200 IU of Vitamin E per day for adults), Vitamin E esters such as Vitamin E acetate and succinate (alpha-tocopheryl acetate and alpha-tocopheryl succinate) as well as water soluble Vitamin E derivatives. Use of water soluble Vitamin E derivatives is preferred.

Water soluble Vitamin E derivatives include pharmaceutically acceptable Vitamin E salts such as Vitamin E phosphate, as well as water soluble tocopheryl polyethylene glycol esters such as those disclosed in U.S Patent Nos. 2,680,749, 3,914,430 and 5,234,695; water soluble tocopheryl polyethylene glycol esters are preferred.

Use of d-alpha-tocopheryl polyethylene glycol esters such as the water dispersible Vitamin E d-alpha-tocopheryl polyethylene glycol 1000 succinate ("Vitamin E-TPGS") as well as use of compositions of Vitamin E-TPGS and at least one fatty acid ester of glycerine having an overall melting point of 40°C (both of which are disclosed in U.S. Patent 5,234,695 and available from Eastman Kodak Co., Rochester, NY) are more preferred.

The effective amounts of Vitamin E derivatives, e.g., water soluble Vitamin E derivatives such as Vitamin E-TPGS is in the range of about 200 IU to 20000 IU of Vitamin E /day, preferably about 1000 IU to about 5000 IU of Vitamin E /day, more preferably about 1200 IU to about 2200 IU of Vitamin E /day, in single or divided doses. Dimitrov,NV, et al., Am J Clin Nutr(USA) Sept. 1996, Vol. 64, (3) pages 329-335 reports that administration of 400 IU (269 mg), 800 IU (537 mg) and 1200 IU (807 mg) of Vitamin E-TPGS to healthy volunteers as a single oral dose resulted slight elevation of plasma alpha tocopherol concentrations. Sokool,RJ, et al. Gastroenterology,(USA), June 1993, Vol. 104(6) pages 1727-1735 report that a dose of 20-25IU/kg/day of Vitamin E-TPGS appears to be safe and effective for treating chronic childhood cholestasis. The RDA of Vitamin E-TPGS for pediatrics is in the range of 15-25IU/kg/day.

Vitamin C (L-ascorbic acid and D-ascorbic acid)is readily available as an over the counter product. See also Merck Index, 11th Edition #855 pp. 130-131. The RDA for Vitamin C is in the range of about 100 to about 200 mg/day, but the use of doses of up to 25 g/day or even 40 g/day have been reported.

Silybum marianum (silymarin), the active ingredient in milk thistle, is available from Magdaus AG, Germany under the LEGALON trade name. The RDA for silymarin is 140 mg/day, capsule, PO. .

Coenzyme -Q10 is a vitamin-like substance made by the human body and is also found in organ meats. The RDA for coenzyme -Q10 is about 300 to 400 mg/day .

BHA (butylated hydroxyanisole) (Merck Index, 11th Edition, No. 1547) and BHT (butylated hydroxytoluene (Merck Index, 11th Edition, No. 1548 p. 238) are available from Aldrich Chemical Company Inc., Milwaukee, WI 53233.

Acetyl cysteine (N-Acetyl-L-cysteine, "NAC") is found in the body. See also Merck Index, 11th Edition, No. 82 p. 14 .The RDA for NAC is in the range of about 300 mg/day to 600 mg/day.

5 Selenium is available from Aldrich Chemical Company Inc., Milwaukee, WI 53233. The RDA for selenium is 200 to 600 micrograms/day.

10 Panavia (4,4'-isopropylidenedithiobis-2,6-di-t-butylphenol) is available from Vyrex Corporation, LaJolla, CA 92037 (USA). The RDA for Panavia 200 mg to 800 mg/day PO for HIV patients ; higher doses stablized or slightly stabilized CD4 levele in Phase I/II clinical trials. See PharmaProjects, section J5A

15 Lycopene is found in tomatoes; see NY TIMES, April 13,1999, Science Times Section page F 12 . The RDA for lycopene is in the range of 5 to 15 mg/day.

20 The preferred antioxidants are water soluble d-alpha-tocopheryl polyethylene glycol esters such as the water dispersible Vitamin E d-alpha-tocopheryl polyethylene glycol 1000 succinate("Vitamin E-TPGS") as well as use of compositions of Vitamin E-TPGS and at least one fatty acid ester of glycerine having an overall melting point of 40°C (both of which are disclosed in U.S. Patent 5,234,695 and available from Eastman Kodak Co., Rochester, NY).

25 Pharmaceutical compositions of the antioxidants suitable for oral, parenteral and topical administration and useful in the present invention may contain the excipient, and other ingredient found in the over the counter preparations of the antioxidants. Compositions of Vitamin E-TPGS and at least one fatty acid ester of glycerine having an overall melting point of 40°C disclosed in U.S. Patent 5,234,695 may also be used. See also the compositions of Trolox  
30 and Trolox C disclosed in J Pharm Pharmacol( GB), Feb 1995, Vol 47(2), pages 138-142.

The *in vitro* inhibitory concentrations of ribavirin are disclosed in Goodman & Gilman's "The Pharmacological Basis of Therapeutics", Ninth Edition, (1996) McGraw Hill, NY, at pages 1214-1215. The Virazole product information discloses a  
 5 dose of 20 mg/mL of Virazole aerosol for 18 hours exposure in the 1999 Physicians Desk Reference at pages 1382 - 1384.

Ribavirin dosage and dosage regimens are also disclosed by Sidwell, R.W., et al. Pharmacol. Ther 1979 Vol 6. pp123-146 in section 2.2 pp 126-130. Fernandes,  
 10 H., et al., Eur. J. Epidemiol., 1986, Vol 2(1) pp1-14 at pages 4-9 disclose dosage and dosage regimens for oral, parenteral and aerosol administration of ribavirin in various preclinical and clinical studies.

The term "patients having hepatitis C infections" as used herein means any  
 15 patient-including a pediatric patient-having hepatitis C and includes treatment-naive patients having hepatitis C infections and treatment-experienced patients having hepatitis C infections as well as those pediatric, treatment-naive and treatment-experienced patients having chronic hepatitis C infections.

20 These patients having chronic hepatitis C include those who are infected with multiple HCV genotypes including type 1 as well as those infected with, *inter alia*, HCV genotype 2 and/or 3.

The term "pediatric patient" as used herein means a patient below the age  
 25 of 17, and normally includes those from birth to 16 years of age.

The term "treatment-naive patients having hepatitis C infections" as used herein means patients with hepatitis C who have never been treated with ribavirin or any interferon, including but not limited to interferon-alfa, or pegylated  
 30 interferon alfa.

The term "treatment-experienced patients having hepatitis C infections" as used herein means patients with hepatitis C who have been treated with ribavirin or any interferon, including but not limited to interferon-alfa, or pegylated interferon alfa, including relapsers and non-responder.

The term "patients having chronic hepatitis C infections" as used herein means any patient having chronic hepatitis C and includes "treatment-naïve patients and treatment-experienced patients having chronic hepatitis C infections, including but not limited to relapsers and non-responders.

The term "relapsers" as used herein means treatment-experienced patients with hepatitis C who have relapsed after initial response to previous treatment with interferon alone, or in combination with ribavirin.

The term "non-responders" as used herein means treatment-experienced patients with hepatitis C who have not responded to prior treatment with any interferon alone, or in combination with ribavirin.

The term "interferon-alfa" as used herein means the family of highly homologous species-specific proteins that inhibit viral replication and cellular proliferation and modulate immune response. Typical suitable interferon-alfas include, but are not limited to, recombinant interferon alfa-2b such as Intron-A interferon available from Schering Corporation, Kenilworth, N.J., recombinant interferon alfa-2a such as Roferon interferon available from Hoffmann-La Roche, Nutley, N.J., recombinant interferon alfa-2c such as Berofer alpha 2 interferon available from Boehringer Ingelheim Pharmaceutical, Inc., Ridgefield, CT., interferon alpha-n1, a purified blend of natural alfa interferons such as Sumiferon available from Sumitomo, Japan or as Wellferon interferon alpha-n1 (INS) available from the Glaxo-Wellcome Ltd., London, Great Britain, or a consensus alpha interferon such as those described in U.S. Patent Nos. 4,897,471 and 4,695,623 (especially Examples 7, 8 or 9 thereof) and the specific product available from Amgen, Inc., Newbury Park, CA, or interferon alfa-n3 a mixture of natural alfa interferons made by Interferon Sciences and available from the Purdue Frederick Co., Norwalk, CT., under the Alferon Tradename or recombinant interferon alpha available from Fraunhofer Institute, Germany or that is available from Green Cross, South Korea. The use of interferon alfa-2a or

alpha 2b is preferred. Since interferon alpha 2b, among all interferons, has the broadest approval throughout the world for treating chronic hepatitis C infection, it is most preferred. The manufacture of interferon alpha 2b is described in U.S. Patent No. 4,530,901.

5

The term "pegylated interferon alfa" as used herein means polyethylene glycol modified conjugates of interferon alfa, preferably interferon alfa-2a and -2b. The preferred polyethylene-glycol-interferon alfa -2b conjugate is PEG<sub>12000</sub>-interferon alfa 2b. The phrases "12,000 molecular weight polyethylene glycol conjugated interferon alpha" and "PEG<sub>12000</sub>-IFN alfa" as used herein mean conjugates such as are prepared according to the methods of International Application No. WO 95/13090 and containing urethane linkages between the interferon alfa-2a or -2b amino groups and polyethylene glycol having an average molecular weight of 12000.

15

The preferred PEG<sub>12000</sub>-interferon alfa-2b is prepared by attaching a PEG polymer to the epsilon amino group of a lysine residue in the IFN alfa-2b molecule. A single PEG<sub>12000</sub> molecule is conjugated to free amino groups on an IFN alfa-2b molecule via a urethane linkage. This conjugate is characterized by the molecular weight of PEG<sub>12000</sub> attached. The PEG<sub>12000</sub>-IFN alfa-2b conjugate is formulated as a lyophilized powder for injection. The objective of conjugation of IFN alfa with PEG is to improve the delivery of the protein by significantly prolonging its plasma half-life, and thereby provide protracted activity of IFN alfa.

20

Other interferon alfa conjugates can be prepared by coupling an interferon alfa to a water-soluble polymer. A non-limiting list of such polymers include other polyalkylene oxide homopolymers such as polypropylene glycols, polyoxyethylenated polyols, copolymers thereof and block copolymers thereof.

25

As an alternative to polyalkylene oxide-based polymers, effectively non-antigenic materials such as dextran, polyvinylpyrrolidones, polyacrylamides, polyvinyl alcohols, carbohydrate-based polymers and the like can be used. Such interferon alfa-polymer conjugates are described in U.S. Patent No. 4,766,106, U.S. Patent No. 4,917,888, European Patent Application No. 0 236 987, European Patent

30

Application Nos. 0510 356, 0 593 868 and 0 809 996 (pegylated interferon alfa-2a) and International Publication No. WO 95/13090.

Pharmaceutical compositions of pegylated interferon alfa-suitable for parenteral administration may be formulated with a suitable buffer, e.g., Tris-HCl, acetate or phosphate such as dibasic sodium phosphate/monobasic sodium phosphate buffer, and pharmaceutically acceptable excipients ( e.g., sucrose), carriers (e.g. human plasma albumin), toxicity agents (e.g. NaCl), preservatives (e.g. thimerosol, cresol or benylalcohol), and surfactants( e.g. tween or polysorbates) in sterile water for injection. The pegylated interferon alfa-may be stored as lyophilized powders under a refrigeration at 2°-8°C. The reconstituted aqueous solutions are stable when stored between 2° and 8°C and used within 24 hours of reconstitution. See for example U.S. Patent Nos, 4,492,537; 5,762,923 and 5,766,582. The reconstituted aqueous solutions may also be stored in prefilled, multi-dose syringes such as those useful for delivery of drugs such as insulin. Typical suitable syringes include systems comprising a prefilled vial attached to a pen-type syringe such as the NOVOLET Novo Pen available from Novo Nordisk, as well as prefilled, pen-type syringes which allow easy self-injection by the user. Other syringe systems include a pen-type syringe comprising a glass cartridge containing a diluent and lyophilized pegylated interferon alfa powder in a separate compartment.

The following preferred embodiments for administering therapeutically effective amounts of the combination therapy of interferon alfa and ribavirin are presented

25

The interferon-alpha administered as part of the combination therapy is preferably selected from interferon alpha-2a, interferon alpha-2b, a consensus interferon, a purified interferon alpha product or a pegylated interferon-alpha. More preferably, the interferon-alpha is selected from interferon alpha-2a, interferon alpha-2b, or a purified interferon alpha product and the amount of interferon-alpha administered is from 2 to 10 million IU per week on a weekly, TIW, QOD or daily basis. In a preferred embodiment, the interferon-alpha

30



administered is interferon-alpha-2b and the amount of interferon-alpha is administered 3 million IU TIW.

Alternatively, the interferon-alpha administered as part of the combination therapy is consensus interferon and the amount of interferon-alpha administered is from 1 to 20 micrograms per week on a weekly, BIW, TIW, QOD or daily basis. In another embodiment, the interferon-alpha administered is a pegylated interferon alpha-2b and the amount of interferon-alpha administered is from 0.5 to 2.0 micrograms per week on a weekly, BIW, TIW, QOD or daily basis.

Alternatively, the interferon-alpha administered is a pegylated interferon alpha-2a and the amount of interferon-alpha administered is from 20 to 250 micrograms/kilogram per week on a weekly, TIW, QOD or daily basis.

When the pegylated interferon-alfa administered as part of the combination therapy is a pegylated interferon alfa-2b, the therapeutically effective amount of pegylated interferon alfa-2b administered during the treatment in accordance with the present invention, including in first and second treatment time periods, is in the range of about 0.1 to 9.0 micrograms per kilogram of pegylated interferon alfa-2b administered per week, in single or divided doses, preferably once a week (QW) or twice a week (BIW), preferably in the range of about 0.1 to about 9.0 micrograms per kilogram of pegylated interferon alfa-2b administered once a week (QW) or in the range of about 0.05 to about 4.5 micrograms per kilogram of pegylated interferon alfa-2b administered twice a week (BIW), or is in the range of about 0.5 to about 3.0 micrograms per kilogram of pegylated interferon alfa-2b administered per week, preferably in the range of about 0.5 to about 3.0 micrograms per kilogram of pegylated interferon alfa-2b administered once a week (QW) or in the range of about 0.25 to about 1.5 micrograms per kilogram of pegylated interferon alfa-2b administered twice a week, or is in the range of about 0.75 to about 1.5 micrograms per kilogram of pegylated interferon alfa-2b administered per week, most preferably is in the range of about 0.75 to about 1.5 micrograms per kilogram of pegylated interferon alfa-2b administered once a week or about 0.375 to about 0.75 micrograms per kilogram of pegylated interferon alfa-2b administered twice a week.

When the pegylated interferon-alfa administered to pediatric patients as part of the combination therapy is a pegylated interferon alfa-2b, the therapeutically effective amount of pegylated interferon alfa-2b administered during the treatment in accordance with the present invention, including in first and second treatment time periods is in the range of about 0.1 to 9.0 micrograms per kilogram of pegylated interferon alfa-2b administered per week, in single or divided doses, preferably once a week (QW) or twice a week (BIW), more preferably about 0.1 to about 9.0 micrograms per kilogram of pegylated interferon alfa-2b administered once a week (QW), or about 0.05 to about 4.5 micrograms per kilogram of pegylated interferon alfa-2b administered per week, in single or divided doses, preferably once a week (QW) or twice a week (BIW), more preferably about 0.05 to about 4.5 micrograms per kilogram of pegylated interferon alfa-2b administered once a week, or preferably about 0.75 to about 3.0 micrograms per kilogram of pegylated interferon alfa-2b administered in single or divided doses, preferably once a week (QW) or twice a week (BIW), more preferably about 0.75 to about 3.0 micrograms per kilogram of pegylated interferon alfa-2b administered once a week or about 0.375 to about 1.5 micrograms per kilogram of pegylated interferon alfa-2b administered twice a week, and most preferably about 2.25 to about 2.6 micrograms per kilogram of pegylated interferon alfa-2b administered once a week or about 1.1 to about 1.3 micrograms per kilogram of pegylated interferon alfa-2b administered twice a week (BIW).

When the pegylated interferon-alfa administered as part of the combination therapy is a pegylated interferon alfa-2a, the therapeutically effective amount of pegylated interferon alfa-2a administered during the treatment in accordance with the present invention, including in first and second treatment time periods, is in the range of about 50 micrograms to about 500 micrograms once a week ("QW"), preferably about 180 micrograms to about 250 micrograms QW or the effective amount is in the range of about 50 micrograms to about 250 micrograms twice a week, preferably about 90 micrograms to about 125 micrograms twice a week.

When the pegylated interferon-alfa administered to a pediatric patient as part of the combination therapy is a pegylated interferon alfa-2a, the therapeutically effective amount of pegylated interferon alfa-2a administered during the treatment in accordance with the present invention, including in first treatment time period is in the range of about 50 micrograms to about 500 micrograms once a week ("QW"), preferably about 300 micrograms to about 375 micrograms QW or the therapeutically effective amount of pegylated interferon alfa-2a administered to a pediatric patient is in the range of about 50 micrograms to about 250 micrograms twice a week, preferably about 150 micrograms to about 190 micrograms once a week

Ribavirin is administered as part of the combination therapy to the patient in association with pegylated interferon-alfa, that is, before, after or concurrently with the administration of the pegylated interferon alfa. The pegylated interferon-alfa dose is preferably administered during the same period of time that the patient receives doses of ribavirin. The amount of ribavirin administered concurrently with the pegylated interferon-alfa is from about 400 to about 1600 mg per day, preferably about 600 to about 1200 mg/day or about 800 to about 1200 mg day and most preferably about 1000 to about 1200 mg/kg a day. The pegylated interferon-alfa dose is also preferably administered to the pediatric patient during the same period of time that such patient receives doses of ribavirin. The amount of ribavirin administered to the pediatric patient concurrently with the pegylated interferon-alfa is from about 8 to about 15 mg per kilogram per day, preferably about 8, 12 or 15 mg per kilogram per day, in divided doses.

The following preferred embodiments for administering induction dosing amounts of interferon alfa in association with ribavirin in the first and second treatment time periods are presented.

The amount of ribavirin administered in the first treatment time period is from 400 to 1600 mg per day, preferably 600 to 1200 mg/day or about 800 to 1200 mg day and most preferably about 1000 to 1200 mg/kg a day. The amount of ribavirin administered in the second treatment time period is in the range of  
 5 from about 800 to 1200 mg per day, preferably from about 1000 to 1200 mg per day.

When the interferon-alfa administered is selected from interferon alfa-2a, interferon alfa-2b, or a purified interferon alfa product, the therapeutically effective  
 10 induction dosing amount of interferon-alfa administered in the first treatment time period is 10 MIU daily for 2 weeks, followed by 5 MIU daily for 6 weeks, followed by 3 MIU daily for 16 weeks, and the therapeutically effective amount of interferon-alfa administered in the second treatment time period is 3 MIU TIW for  
 15 24 weeks.

When the interferon-alfa administered is interferon-alfa-2b, the therapeutically effective induction dosing amount of interferon-alfa-2b administered in the first treatment time period is 10 MIU daily for 2 weeks, followed by 5 MIU daily for 6 weeks, followed by 3 MIU daily for 16 weeks, and  
 20 the amount of interferon-alfa-2b administered in the second treatment time period is 3 MIU TIW for 24 weeks.

When the interferon-alfa administered is consensus interferon , the amount of consensus interferon administered in the first treatment period of  
 25 twenty-four weeks is from 15 to 20 micrograms on a daily basis for two weeks, followed by 9 to 15 micrograms on a daily basis for twenty-two and the amount of consensus interferon administered in the second treatment period is from 9 micrograms TIW for twenty-four weeks.

In a preferred embodiment of the present invention, the interferon-alfa is  
 30 interferon-alfa-2a or -2b; use of interferon-alfa-2b is more preferred.

The sum of the first and second treatment time periods is about 40-50 weeks, and preferably is 48 weeks.

A person suffering from chronic hepatitis C infection may exhibit one or more of the following signs or symptoms:

- (a) elevated ALT,
- (b) positive test for anti-HCV antibodies,
- (c) presence of HCV as demonstrated by a positive test for HCV-RNA,
- (d) clinical stigmata of chronic liver disease,
- (e) hepatocellular damage.

To practice the invention, the combination therapy of interferon-alfa and ribavirin or inducing dosing amounts of interferon-alfa and ribavirin are administered to the patient exhibiting one or more of the above signs or symptoms in amounts sufficient to eliminate or at least alleviate one or more of the signs or symptoms. The therapeutically effective amount of the antioxidant is administered in association with the combination therapy or induction dosing amounts to ameliorate the ribavirin-related hemolysis.

Ribavirin is administered to the patient in association with the interferon-alfa, that is, the interferon-alfa dose is administered during the same period of time that the patient receives doses of the ribavirin derivative of the present invention. Most interferon-alfa formulations are not effective when administered orally, so the preferred method of administering the interferon-alfa is parenterally, preferably by subcutaneous, IV, or IM, injection. Ribavirin may be administered orally in capsule or tablet form in association with the parenteral administration of interferon-alfa. Of course, other types of administration of both medicaments, as they become available are contemplated, such as by nasal spray, transdermally, by suppository, by sustained release dosage form, etc. Any form of administration will work so long as the proper dosages are delivered without destroying the active ingredient.

Pharmaceutical composition of interferon- alfa, suitable for parenteral administration may be formulated with a suitable buffer, e.g., Tris-HCl, acetate or phosphate such as dibasic sodium phosphate/monobasic sodium phosphate buffer, and pharmaceutically acceptable excipients ( e.g., sucrose), carriers (e.g. human serum albumin), toxicity agents (e.g. NaCl), preservatives (e.g. thimerosol, cresol or benylalcohol), and surfactants( e.g. tween or polysorabates) in sterile water for injection. The interferon alfa-may be stored as lyophilized powders under a refrigeration at 2°-8°C. The reconstituted aqueous solutions are stable when stored between 2° and 8°C and used within 24 hours of reconstitution. See for example U.S. Patent Nos, 4,492,537; 5,762,923 and 5,766,582.

The term “ no detectable HCV-RNA” in the context of the present invention means that there is less than 100 copies of HCV-RNA per ml of serum of the patient as measured by quantitative, multi-cycle reverse transcriptase PCR methodology. HCV-RNA is preferably measured in the present invention by the methodology described below. This methodology is referred to herein as HCV-RNA/qPCR.

The term “ substantially lower detectable HCV-RNA serum levels” in the context of the present invention means that the HCV-RNA serum level is lower by at least a power of ten, preferably lower by two powers of ten and most preferably lower by at least three powers of ten, compared to the initial HCV-RNA serum level.

RNA is extracted from patient serum using a guaninidium thiocyanate-phenol-chloroform mixer followed by ethanol-ammonium acetate precipitation. The precipitated RNA is centrifuged and the resulting pellet is dried in a Centrivap console (Labconco, Kansas City, Mo.). The dry pellet is then resuspended in 30 microliters of an Rnasin (Promega Corp., Madison, WI), dithiothritol, and diethylpyrocarbonate-treated water mixture. Samples are kept at or below -20°C (preferably below -70°C) until RNA reverse transcription (RT) and PCR.

In order to convert the entire RNA sequence into cDNA in the RT reaction, random hexadeoxyribonucleotides (Pharmacia Biotech, Piscataway, NJ) are used as primers for the first strand cDNA synthesis. Two aliquots of 3 microliters of resuspended sample is added to 3 microliters of 100ng/ $\mu$ l random primers and denaturated at 70°C, then reverse transcribed at 40°C for one hour using M-MLV reverse transcriptase (USB, Cleveland, OH) in standard buffer containing 5 mM MgCl<sub>2</sub>. The final RT reaction volume is 26  $\mu$ l. The PCR is started immediately following the reverse transcription.

A modified version of the PCR method is performed using heat-stable Taq polymerase to amplify the cDNA. Seventy-five microliters of PCR mix is added to the entire RT reaction volume (26  $\mu$ l) to a final MgCl<sub>2</sub> concentration of 1.5 mM in a total volume of 101  $\mu$ l. Each 101  $\mu$ l sample is then split into 50.5  $\mu$ l, and a layer of mineral oil is placed on top to prevent evaporation.

The PCR cycle consists of annealing for 90 sec., extension for 90 sec., and denaturation for 90 sec., at 55°C, 74°C and 94°C, respectively. Thermocycling samples is submitted to a final 74°C extension for 10 minutes. Four different cycle sets are used. By loading the sample in duplicate, and splitting these samples evenly after RT, there are four tubes from one sample. Each of the four tubes is given a different cycle number, enhancing sensitivity and accuracy in the quantitation process. The thermocycling efficiency will be assessed by satisfactory amplification of known copy number RNA standards included in each set of 60 tubes. Two primer sets are used for the amplification, both from the 5' untranslated region of the HCV genome. Both of these primer sets are highly conserved and detect all known subtypes of HCV. Primer set 1: upstream 5' - GTG GTC TGC GGA ACC GGT GAG T-3', downstream 5'-TGC ACG GTC TAC GAG ACC TC-3' which produced a 190 bp product. Primer set 2: upstream 5'-CTG TGA GGA ACT ACT GTC TTC-3', downstream 5'-CCC TAT CAG GCA GTA CCA CAA-3' which produced a 256 bp product.

The amplified cDNA is then electrophorised in 3% agarose gel and transferred to nylon membrane. The target DNA is detected by Southern blotting and immunostaining using a nonradioactive digoxigenin-labeled DNA probe.

These procedures are performed using automated instruments for PCR

5 thermocycling, agarose gel electrophoresis, vacuum-transfer Southern blot, hybridization, and immunostaining. Each membrane contains known copy number serially diluted standards which are used to construct standard curves for quantitative measurement of the specimen bands. Originally standard curves are made from carefully diluted HCV-RNA from transcribed clones. Radioactive  
10 incorporation studies, gel electrophoresis, and OD 260 are performed on the transcripts to determine that they are of the expected length. After the production of the RNA transcripts quantitated clone standards "pooled" standards are generated which better represent the heterogeneous nature of HCV, one would encounter in natural infection. These pools are made by combining large  
15 amounts of serum or plasma from known infected individuals. The serum/plasma pools are calibrated with PCR, against the clone transcripts and then diluted in the known PCR-negative fluids. Finally, the higher copy number samples of the pools are checked against the cDNA Quantiplex nucleic acid detection system from Chiron Inc. (Emeryville, CA). These "double quantitated" pools are aliquoted  
20 and saved at -70°C. Dilutions of 5,000,000, 1,000,000, 500,000, 100,000, 10,000, and 1000 copies/ml are used in each experiment.

Each Southern blot membrane is scanned into a computer using an automated scanner/densitometer, at intervals during development to determine  
25 when the standard curve is most linear. The resultant electronic images are then measured for band area and mean band density. All of the reading are standardized to integrated band density and compared to the standard curve to obtain a numerical value of viral copy number for each band.

The term "sustained virologic response" as used in the context of the  
30 present invention means that there is no detectable HCV-RNA in the patients treated in accordance with the present invention for at least 24 weeks after the



end of the combined therapy treatment. Preferably, the period of sustained virologic response will be at least one year - or longer - after the end of treatment.

During treatment and post-treatment follow-up, biochemical (ALT),  
 5 virological (HCV-RNA), hematology, including at least the following  
 hemoglobin(HgB), hematocrit(HCT). RBC, WBC with differential and platelet  
 counts) levels and histological (liver biopsy) examinations would be used to  
 assess the nature and duration of response to study treatment. The primary  
 efficacy variable will be the overall response defined as loss of serum HCV-  
 10 RNA/qPCR (<100 copies/mL) as measured at 24 weeks following the end of  
 therapy. In addition, the drop in the hemoglobin levels compared to baseline values  
 will also be measured . In addition, a decrease in hepatic inflammation, an  
 improvement in post-treatment liver biopsy as measured by the Knodell Histology  
 Activity index (HAI) and normalization of ALT will also be examined as a  
 15 secondary efficacy endpoints. The safety of the study treatments will be  
 assessed by monitoring selected laboratory parameters and by also recording  
 and evaluating the occurrence of any adverse events.

### Efficacy

20 The primary efficacy objective will be the comparison of the treatment groups  
 1 and 2 with respect to the sustained virologic response rate defined as loss of  
 (detectable) serum HCV-RNA/qPCR measured at 24 weeks following the end of  
 therapy to an undetectable level or to a level <100 copies/mL. The following  
 secondary efficacy Endpoints will also be examined using logistic regression:

25 The secondary efficacy Endpoints:

- proportions of patients with normalization of ALT at 24 weeks of follow-up;
- proportions of patients with improvement in biopsy (Categories I + II +III combined scores);

- changes from Baseline in the biopsy scores (Categories I + II + III combined scores);
- response rates at Endpoint of treatment based on HCV-RNA/qPCR;
- proportion of patients with normalization of ALT at Endpoint of treatment.
- response rates at 24 weeks of follow-up based on HCV-RNA/qPCR.

### Virology: Entry Status and Change from Entry

Serum HCV-RNA/qPCR testing and HCV genotype testing will be performed by a central laboratory. A positive HCV-RNA assay result will be required at Baseline; only patients positive for HCV-RNA will be eligible to participate. Repeat assays should be scheduled at Weeks 4, 12, 24, and if the patient is in the 48 week treatment groups at weeks 36 and 48. All patients should have repeat assays scheduled for Follow-up Weeks 12 and 24.

Response will be assessed as defined below:

10

#### **Virologic Responder:**

A patient will be classified as a responder at a given time point if HCV-RNA/qPCR is negative (<100 copies per mL) at that time point.

15

#### **Sustained Virologic Responder:**

A patient will be classified as a sustained responder if the patient is a responder at 24 weeks of follow-up.

20

Note that patients who do not meet these criteria, including patients who discontinued before the required HCV-RNA/qPCR evaluations are obtained, will be classified as non-responders.

25

#### **Overall Responder:**

Based on both serum HCV-RNA/qPCR and change in liver histology as evaluated by the Knodell HAI Inflammation Score. A patient will be classified as an overall responder to treatment if at 24 weeks of follow-up, he/she is a sustained virologic responder and has normal ALT.

### Liver Histology

5 Liver biopsy will be taken within the six months preceding patient enrollment and at Follow-up Week 24 for all patients. Evaluation of the biopsies will be performed by a single pathologist using the Knodell Histology Activity Score. The central pathologist will be blinded with respect to patient identification, treatment group, and the time the biopsy will be obtained relative to treatment (Pre- or Post-treatment). Efficacy of study treatments will be assessed by comparing the  
10 degree of inflammatory activity observed at Baseline with that present at Follow-up Week 24.

15 The patient's weight and their baseline disease characteristics (HCV genotype, hemoglobin levels and initial viral load) for all patients will be measured before the start of the study . HCV genotypes should be done on the patient serum samples subjected to HCV-RNA/qPCR testing.

This enhancement of efficacy included all aspects of the disease will result in:

- 20 • Sustained eradication of detectable **HCV-RNA**;
- Improvement in hepatic inflammation;
- Lower Hemoglobin Drops ;
- Normalization of ALT;
- Improvement in HQL.

## CLINICAL STUDY DESIGN

This is a treatment protocol designed to confirm the efficacy of Vitamin E shown in the pilot study discussed herein above in the amelioration of hemolysis associated with Rebetrone (Intron A + Ribavirin) for treatment of patients with chronic hepatitis C.

The following double blind treatment arms will be randomly assigned to patients at selected centers under this protocol:

A. Rebetrone (Intron A 3MU TIW \_ Ribavirin 1000-12000 mg po daily in divided doses) plus 1000 IU of Vitamin E, BID.

B. Rebetrone (Intron A 3MU TIW + Ribavirin 1000 – 12000 mg po daily in divided doses) plus 1000 IU of Vitamin E plus placebo.

C. Rebetrone (Intron A 3MU TIW + Ribavirin 1000 – 12000 mg po daily in divided doses) plus Matched placebo only.

Patients must weigh  $\geq 75$  kg will receive 1200 mg/day of ribavirin.

Treatment will be discontinued if patients do not clear virus by 6 months.

A total of 90 patients will be enrolled (30 patients per group)..

## OBJECTIVES

The primary objective of this treatment protocol is to confirm that Vitamin E can reduce the hemolysis that occurs with the use of ribavirin, (a reduction in the drop of hemoglobin from baseline compared to control).

The secondary objectives are to determine if there is a decrease need for ribavirin doses reductions, a decrease in patient discontinuations from therapy and an improved quality of life.

5

## STUDY SYNOPSIS

The protocol is a double blind randomized study of standard dose Rebetron (Intron A 3 mu TIW + Ribavirin 1000-12000 mg/d) plus 1000 IU of Vitamin E or 2000 IU of Vitamin E or Placebo. Serial hemoglobin levels, HCV RNA levels and ribavirin levels will be drawn. Other markers of hemolysis and a quality of life tool (vitality and depression scales) will be used to also measure outcomes. Interim analysis will be done off site at weeks 12 and 24 while investigator sites remain blinded.

15

## STUDY POPULATION

Adult male and female patients with compensated, chronic hepatitis C who have not received previous treatment with interferon. Patients meeting the following Inclusion Criteria will be enrolled.

20

### Inclusion Criteria:

The patient must meet the following criteria for entry:

25

Adult male or female, age of 18 to 70.

Serum positive for hepatitis C virus by PCR.

30

Liver biopsy prior to entry to this protocol with a pathology report confirming that the historical diagnosis is consistent with chronic hepatitis.

Compensated liver disease with the following laboratory parameters at the Entry visit:

Hemoglobin values of > 11 g/dL for females or > 12 g/dL for males

WBC > 3,000/mm<sup>3</sup>

5 Neutrophil count 1,500/mm<sup>3</sup>

Platelets > 70,000/mm<sup>3</sup>

Prothrombin time < 2 seconds prolonged compared to control, or equivalent INR ratio

Bilirubin within 20% of the upper limit of normal.

10 Albumin >3.5 g/dL.

Serum creatinine < 1.4 mg/dL

Fasting blood sugar < 115 mg/dL for non-diabetic patients

Hemoglobin A < 8.5% for diabetic patients (whether on medication and/or diet controlled).

15 Thyroid Stimulating Hormone (TSH) within normal limits

Antinuclear antibodies (ANA) <1:160.

Alpha fetoprotein (AFP) value within normal limits obtained within the prior year. For patients with results above the upper limit of normal but < 50 ng/mL both of the following are required:

20

Alpha fetoprotein value < ng/mL obtained within 3 months prior to entry and Ultrasound obtained within 3 months prior to entry that is negative for evidence of hepatocellular carcinoma.

25

### Exclusion Criteria

The patient will be excluded from entry if any of the following criteria apply:

Hypersensitivity to alpha interferon or ribivirin.

Any other causes for chronic liver disease other than chronic hepatitis C.

30 Hemoglobinopathies (e.g., Thalassemia) or any other cause of hemolytic anemia.

Evidence of advanced liver disease such as a history of or presence of ascites, bleeding varices, or spontaneous encephalopathy.

Any known preexisting medical condition that could interfere with the patients participation in the protocol including: CNS trauma or active seizure disorders requiring medication; poorly controlled diabetes mellitus; serious pulmonary disease; immunologically-mediated diseases; gout; or any medical condition requiring, or likely to require during the course of the study, chronic systemic administration of steroids.

Patients with evidence of ischemia on stress testing (required for patients at risk of or with a history of coronary artery disease; ECG evidence of ischemia, an arrhythmia, cardiac failure, coronary surgery, uncontrolled hypertension, angina or a myocardial infarction within 12 months.

Patients with clinically significant retinal abnormalities.

Substance abuses, such as alcohol (80 g/day) I.V. drugs and inhaled drugs. If the patient has a history of substance abuse, to be considered for inclusion into the protocol, the patient must have abstained from using the abused substance for at least 1 year. Patients receiving a methadone within the past year are also excluded.

Patients must be counseled with regard to the need to abstain from the consumption of alcohol. Patients with an alcohol consumption of > 20 g/day are ineligible for the protocol.

Concurrent use of nucleoside analogs, amantadine/rimantadine, and protease inhibitors will be excluded.

Patients with a history of organ transplantation with be excluded.



Pre-existing psychiatric conditions; especially severe depression, or a history of severe psychiatric disorder, such as major psychoses, suicidal ideation and/or suicidal attempt are excluded.

5

## STUDY MEDICATION

### Ribavirin Supplies

10

Study medication will be provided in the standard packaging of Rebetron. Ribavirin will be provided by the patient's pharmacy, directly from office dispensing or through Schering's Commitment to Care program. Ribavirin capsules must be stored at room temperature of 15-25°C(59-77°F).

15

### Administration of Ribavirin

Ribavirin will be administered by the oral route twice daily (BID) at doses ranging from 600 to 1200 mg per day. Ribavirin doses above 800 mg will be based patient weight at the Entry visit as indicated on the following table:

20

**Table**

	<b><u>Ribavirin Dose Capsules/Dose</u></b>	<b><u>Patient Weight</u></b>	<b><u>Total Daily Dose</u></b>	<b><u>Regimen (200 mg each)</u></b>	<b><u>Total Number</u></b>
5					
		<75 kg	1000mg	400 mg/600 mg divided doses, BID,	2 capsules am
10					3 capsules pm
		≥ 75 kg	1200 mg	600 mg/600 mg divided doses , BID	3 capsules am
15					3 capsules pm

All ribavirin doses will be administered on a BID schedule. If an adverse event occurs for which a dose reduction is required, the Total Daily Dose should be adjusted.

### **Intron A Supplies**

Intron A will be obtained by the patient in the appropriate strength in order to provide doses of 3 MU TIW. This will be obtained from the patient's pharmacy, directly from office dispensing, or through Schering Corporation's Commitment to Care program.

### **Administration of Intron A**

Intron A will be administered by the subcutaneous route.. Please see the Intron A Package Insert for additional information.

Vitamin E/placebo supplies and administration.

Vitamin E (available from R.P.Scherer Corp, St Petersburg, FLA) will be supplied in capsule form of 500 IU of Vitamin E strength. The capsules will be packaged in a generic bottle. Appropriately matched placebo capsules will also be supplied in

generic bottles. These will be supplied directly from Schering-Plough Corporation. Capsules will be packaged in 1 month supplies in accordance with the study group (vitamin E/vitamin E), vitamin E/placebo, or placebo/placebo). Each patients will take two capsules AM and two capsules PM on a daily basis as follows:for the study group (vitamin E/vitamin E)- two 500 IU vitamin E capsules AM and two vitamin E capsules PM.;for the study group (vitamin E/ placebo)- two 500 IU vitamin E capsules AM and two placebo capsules PM.; and :for the study group (placebo / placebo)- two placebo capsules AM and two placebo capsules PM.

### **Duration of Treatment.**

Duration of treatment with both Intron A and ribavirin will be for up to 48 weeks.

We expect that the use of antioxidants in association with the combination therapy in accordance with the Clinical Study Design of the present invention will markedly lower the severity of the ribavirin-related hemolytic anemia in the first twelve weeks of the combination therapy - and continue to maintain a lowerer ribavirin-related hemolytic anemia level- throughout the duration of the combination therapy- compared to historical controls

## WHAT IS CLAIMED:

1. A method for treating a patient having a susceptible viral infection which  
5 comprises administering to said patient a therapeutically effective amount of  
ribavirin for a time sufficient to lower viral-RNA in association with a  
therapeutically effective amount of an antioxidant for a time sufficient to  
ameliorate ribavirin-related hemolysis.
- 10 2. The method of claim 1 wherein the interferon alfa is interferon alfa-2a,  
interferon-alfa-2b, pegylated interferon alfa-2a, pegylated interferon alfa-2b,  
or a consensus interferon or a purified interferon alfa product.
- 15 3. The method of claim 1 wherein the antioxidant is Vitamin A, Vitamin E,  
Vitamin C, coenzyme-Q10, BHA, BHT, N-acetylcysteine, selenium, panavir,  
silybum marianum ,lycopene, or mixtures thereof.
- 20 4. The method of claim 3 wherein the Vitamin E is a water soluble Vitamin E  
derivative.
5. The method of claim 4 wherein the water soluble Vitamin E derivative is an  
alpha-tocopheryl polyethylene glycol ester.
- 25 6. The method of claim 5 wherein the water soluble Vitamin E derivative is an  
alpha-tocopheryl polyethylene glycol succinate ester
7. A method of treating a patient having chronic HCV infection which comprises  
administering to said patient a therapeutically effective amount of a  
combination therapy of interferon-alfa and ribavirin for a time sufficient to  
30 lower HCV-RNA in association with a therapeutically effective amount of an  
antioxidant for a time sufficient to ameliorate ribavirin-related hemolysis.

8. The method of claim 7 wherein the interferon alfa is interferon alfa-2a, interferon-alfa-2b, pegylated interferon alfa-2a, pegylated interferon alfa-2b, or a consensus interferon or a purified interferon alfa product.
- 5 9. The method of claim 7 wherein the antioxidant is Vitamin A, Vitamin E, Vitamin C, coenzyme-Q10, BHA, BHT, N-acetylcysteine, selenium, panavir, silybum marianum, lycopene, or mixtures thereof.
- 10 10. The method of claim 9 wherein is a water soluble Vitamin E derivative is used.
11. The method of claim 10 wherein the water soluble Vitamin E derivative is an alpha-tocopheryl polyethylene glycol ester.
- 15 12. The method of claim 11 wherein the water soluble Vitamin E derivative is an alpha-tocopheryl polyethylene glycol succinate ester
- 20 13. The method of claim 7 wherein the combination therapy comprising 3MIU TIW of interferon alfa-2b and about 600 mg to about 1600 mg/day PO of ribavirin is administered for a first time period of at least about 24 weeks.
14. The method of claim 7 wherein the combination therapy is administered for time period at least about 48 weeks.
- 25 15. The method of claim 13 which further comprises administering about 600 to about 1600 mg per day of ribavirin in association with the antioxidant for a second time period of at least about 24 weeks after the end of the first time period.
- 30 16. The method of claim 14 which further comprises administering about 600 to about 1600 mg/day of ribavirin in association with the antioxidant for a third time period of at least about 24 weeks after the end of the first time period.

17. The method of claim 7 wherein the combination therapy comprises about 0.5 to about 1.5  $\mu\text{g/kg/day}$  QW of pegylated interferon alfa-2b and about 600 to about 1600 mg/day of ribavirin.

5

18. The method of claim 7 wherein the combination therapy comprises induction dosing amount of interferon alfa-2b and ribavirin.

19. The method of claim 7 wherein the combination therapy comprises induction therapy dosing of pegylated interferon alfa and ribavirin.

10

20. A method of treating a patient having a chronic HCV infection which comprises administering to said patient for a first time period of at least about 24 weeks a therapeutically effective amount of interferon alfa and ribavirin sufficient to lower detectable HCV-RNA in association with a therapeutically effective amount of an antioxidant sufficient to ameliorate ribavirin-related hemolysis.

15

21. The method of claim 20 wherein the interferon alfa is interferon alfa-2a, interferon-alfa-2b, pegylated interferon alfa-2a, pegylated interferon alfa-2b, or a consensus interferon or a purified interferon alfa product.

20

22. The method of claim 20 wherein the antioxidant is Vitamin A, Vitamin E, Vitamin E, Vitamin C, coenzyme-Q10, BHA, BHT, N-acetyl cysteine, selenium, panavir, silybum marianum, lycopene, or mixtures thereof.

25

23. The method of claim 22 wherein a water soluble Vitamin E derivative is used.

30

24. The method of claim 23 wherein the water soluble Vitamin E derivative is an alpha-tocopheryl polyethylene glycol ester.

25. The method of claim 24 wherein the water soluble Vitamin E derivative is an alpha-tocopheryl polyethylene glycol succinate ester.
- 5 26. The method of claim 20 wherein the combination therapy comprising 3MIU TIW of interferon alfa-2b and about 600 mg to about 1600 mg/day PO of ribavirin is administered for a first time period of at least about 24 weeks.
- 10 27. The method of claim 26 wherein the combination therapy is administered for first time period at least about 48 weeks.
- 15 28. The method of claim 27 which further comprises administering about 600 to about 1600 mg per day of ribavirin in association with the antioxidant for a second time period of at least about 24 weeks after the end of the first time period.
- 20 29. The method of claim 27 which further comprises administering about 600 to about 1600 mg/day of ribavirin in association with the antioxidant for a second time period of at least about 24 weeks after the end of the first time period.
- 25 30. The method of claim 20 wherein the combination therapy comprises about 0.5 to about 1.5  $\mu\text{g/kg/day}$  QW of pegylated interferon alfa-2b and about 600 to about 1600 mg/day of ribavirin.
- 30 31. The method of claim 14 wherein the combination therapy comprises induction dosing amount of interferon alfa-2b and ribavirin. .
32. A method of treating a patient having a chronic HCV infection which comprises (a) administering to said patient for a first time period a therapeutically effective amount of a combination therapy of interferon alfa and ribavirin sufficient to lower detectable HCV-RNA in association

with a therapeutically effective amount of an antioxidant sufficient to ameliorate ribavirin-related hemolysis; and (b) thereafter administering about 600 to about 1600 mg/day of ribavirin in association with the antioxidant for a second time period of at least about 24 weeks after the end of the first time period.

33. The method of claim 32 wherein the interferon alfa is interferon alfa-2a, interferon-alfa-2b, pegylated interferon alfa-2a, pegylated interferon alfa-2b, or a consensus interferon or a purified interferon alfa product.

34. The method of claim 32 wherein the combination therapy comprising 3MIU TIW of interferon alfa-2b and about 600 mg to about 1600 mg/day PO of ribavirin is administered for a first time period of at least about 24 weeks.

35. The method of claim 32 wherein the combination therapy is administered for first time period at least about 48 weeks.

36. The method of claim 32 wherein the combination therapy comprises about 0.5 to about 1.5  $\mu\text{g/kg/day}$  QW of pegylated interferon alfa-2b and about 600 to about 1600 mg/day of ribavirin.

37. The method of claim 32 wherein the combination therapy comprises induction dosing amounts of interferon alfa-2b and ribavirin.

38. The method of claim 32 wherein the antioxidant is Vitamin A, Vitamin E, tocopherol, Vitamin C, coenzyme-Q10, BHA, BHT, N-acetyl cysteine, selenium, panavir, silybum marianum, lycopene, or mixtures thereof.

39. The method of claim 32 wherein a water soluble Vitamin E derivative is used.



40. The method of claim 39 wherein the water soluble Vitamin E derivative is an alpha-tocopheryl polyethylene glycol ester.
41. The method of claim 39 wherein the water soluble Vitamin E derivative is an alpha-tocopheryl polyethylene glycol succinate ester.
42. A method of treating patients having chronic hepatitis C infection to eradicate detectable HCV-RNA comprising (a) administering to said patient, in a first treatment time period of twenty-four weeks, a therapeutically effective amount of an antioxidant sufficient to ameliorate ribavirin-related hemolysis in association with a combination of about 800 to 1200 mg per day of ribavirin and a therapeutically effective amount of interferon-alfa-2b in accordance with the following regimen: about 10 MIU daily of interferon-alfa-2b for two weeks, followed by 5 MIU daily of interferon-alfa for six weeks, followed by 3 MIU daily of interferon-alfa for sixteen weeks, followed by (c) administering in a second treatment time period of twenty-four weeks about 800 to 1200 mg per day of ribavirin and 3 MIU TIW of interferon-alfa in association, a therapeutically effective amount of an antioxidant sufficient to ameliorate ribavirin-related hemolysis.
43. The method of claim 42 wherein the antioxidant is Vitamin A, Vitamin E, Vitamin C, coenzyme-Q10, BHA, BHT, N-acetyl cysteine, selenium, panavir, silybum marianum, lycopene, or mixtures thereof.
44. The method of claim 42 wherein a water soluble Vitamin E derivative is used.
45. The method of claim 42 wherein the water soluble Vitamin E derivative is an alpha-tocopheryl polyethylene glycol ester.

46. The method of claim 42 wherein the water soluble Vitamin E derivative is an alpha-tocopheryl polyethylene glycol succinate ester.

**ABSTRACT OF THE DISCLOSURE**

Methods of treating patients having susceptible viral infections, especially chronic hepatitis C infection by administering to said patient a therapeutically effective amount of a combination therapy of interferon-alfa and ribavirin for a time sufficient to lower HCV-RNA in association with a therapeutically effective amount of an antioxidant for a time sufficient to ameliorate ribavirin-related hemolysis are disclosed.

10

Please type a plus sign (+) inside this box → ☐

PTO/SB/01 (12-97)  
Approved for use through 9/30/00. OMB 0651-0032  
Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE  
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

<b>DECLARATION FOR UTILITY OR DESIGN PATENT APPLICATION (37 CFR 1.63)</b>  <input checked="" type="checkbox"/> Declaration Submitted with Initial Filing    OR <input type="checkbox"/> Declaration Submitted after Initial Filing (surcharge (37 CFR 1.16 (e)) required)	<b>Attorney Docket Number</b>	IN01023K
	<b>First Named Inventor</b>	BRASS
	<b>COMPLETE IF KNOWN</b>	
	<b>Application Number</b>	/
	<b>Filing Date</b>	April 18, 2000
	<b>Group Art Unit</b>	To Be Assigned
	<b>Examiner Name</b>	To Be Assigned

**As a below named inventor, I hereby declare that:**

My residence, post office address, and citizenship are as stated below next to my name.

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled:

HCV COMBINATION THERAPY

the specification of which (Title of the Invention)

☒ is attached hereto  
OR  
☐ was filed on (MM/DD/YYYY) as United States Application Number or PCT International Application Number and was amended on (MM/DD/YYYY) (if applicable).

I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment specifically referred to above.

I acknowledge the duty to disclose information which is material to patentability as defined in 37 CFR 1.56.

I hereby claim foreign priority benefits under 35 U.S.C. 119(a)-(d) or 365(b) of any foreign application(s) for patent or inventor's certificate, or 365(a) of any PCT international application which designated at least one country other than the United States of America, listed below and have also identified below, by checking the box, any foreign application for patent or inventor's certificate, or of any PCT international application having a filing date before that of the application on which priority is claimed.

Prior Foreign Application Number(s)	Country	Foreign Filing Date (MM/DD/YYYY)	Priority Not Claimed	Certified Copy Attached?	
				YES	NO
			<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
			<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
			<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
			<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>

☐ Additional foreign application numbers are listed on a supplemental priority data sheet PTO/SB/02B attached hereto:

I hereby claim the benefit under 35 U.S.C. 119(e) of any United States provisional application(s) listed below.

Application Number(s)	Filing Date (MM/DD/YYYY)	<input type="checkbox"/> Additional provisional application numbers are listed on a supplemental priority data sheet PTO/SB/02B attached hereto.
60/129,991	4/19/99	

[Page 1 of 2]

<b>CERTIFICATE OF MAILING</b>		
I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231 on this date:		
Typed or printed name		
Signature		Date

Express Mail Label No.	EL226883706US
Date	April 18, 2000

Please type a plus sign (+) inside this box → ☐

PTO/SB/01 (12-97)  
Approved for use through 9/30/00. OMB 0651-0032  
Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

## DECLARATION — Utility or Design Patent Application

I hereby claim the benefit under 35 U.S.C. 120 of any United States application(s), or 365(c) of any PCT international application designating the United States of America, listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States or PCT international application in the manner provided by the first paragraph of 35 U.S.C. 112, I acknowledge the duty to disclose information which is material to patentability as defined in 37 CFR 1.56 which became available between the filing date of the prior application and the national or PCT international filing date of this application.

U.S. Parent Application or PCT Parent Number	Parent Filing Date (MM/DD/YYYY)	Parent Patent Number (if applicable)

☐ Additional U.S. or PCT international application numbers are listed on a supplemental priority data sheet PTO/SB/02B attached hereto.

As a named inventor, I hereby appoint the following registered practitioner(s) to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith:

☐ Customer Number

OR

☒ Registered practitioner(s) name/registration number listed below

Place Customer  
Number Bar Code  
Label here

Name	Registration Number	Name	Registration Number
THOMAS D. HOFFMAN	28221		

☒ Additional registered practitioner(s) named on supplemental Registered Practitioner Information sheet PTO/SB/02C attached hereto.

Direct all correspondence to: ☐ Customer Number or Bar Code Label

OR ☒ Correspondence address below

Name	THOMAS D. HOFFMAN				
Address	Patent Dept. K-6-1, 1990				
Address	2000 Galloping Hill Road				
City	Kenilworth	State	NJ	ZIP	07033-0530
Country	USA	Telephone	(908) 298-5037	Fax	(908) 298-5388

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under 18 U.S.C. 1001 and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Name of Sole or First Inventor:

☐ A petition has been filed for this unsigned inventor

Given Name (first and middle (if any))		Family Name or Surname					
CLIFFORD A.		BRASS					
Inventor's Signature			Date				
Residence: City	Scotch Plains	State	NJ	Country	USA	Citizenship	USA
Post Office Address	19 Travelers Way						
Post Office Address							
City	Scotch Plains	State	NJ	ZIP	07076	Country	USA

☐ Additional inventors are being named on the 1 supplemental Additional Inventor(s) sheet(s) PTO/SB/02A attached hereto

Please type a plus sign (+) inside this box → ☐

PTO/SB/02C (3-97)

Approved for use through 9/30/98. OMB 0651-0032

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

## DECLARATION

## REGISTERED PRACTITIONER INFORMATION (Supplemental Sheet)

Name	Registration Number	Name	Registration Number
Margaret M. Albanese	45525	Susan Lee	30653
Edwin P. Ching	34090	Anita W. Magatti	29825
Eric S. Dicker	31669	Arthur Mann	35598
Cynthia L. Foulke	32364	Christine F. Martin	39762
Robert A. Franks	28605	Edward H. Mazer	27573
Kenneth M. Goldman	34174	Jaye P. McLaughlin	41211
James M. Gould	33702	Richard B. Murphy	35296
Richard J. Grochala	31518	James R. Nelson	27929
Henry S. Hadad	35888	David B. Schram	43096
Thomas D. Hoffman	28221	Immac J. Thampoe	36322
Henry C. Jeanette	30856	Paul A. Thompson	35385
Palaiyur S. Kalyanaraman	34634	Donald W. Wyatt	40879
Gerald P. Keleher	43707	Sandy Zaradic	45997
Gabriel P. Kralik	34855		

Burden Hour Statement: This form is estimated to take 0.4 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box →

PTO/SB/02A (3-97)  
Approved for use through 9/30/98. OMB 0651-0032  
Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

## DECLARATION

**ADDITIONAL INVENTOR(S)**  
**Supplemental Sheet**  
Page 1 of 1

**Name of Additional Joint Inventor, if any:**

☐ A petition has been filed for this unsigned inventor

Given Name (first and middle [if any])

Family Name or Surname

PAUL W.

GLUE

**Inventor's  
Signature**

**Date**

**Residence: City**

Flemington

**State**

NJ

**Country**

USA

**Citizenship**

NEW  
ZEALAND

**Post Office Address**

13 Allens Corner Road

**Post Office Address**

**City**

Flemington

**State**

NJ

**ZIP**

08822

**Country**

USA

**Name of Additional Joint Inventor, if any:**

☐ A petition has been filed for this unsigned inventor

Given Name (first and middle [if any])

Family Name or Surname

EDWARD

PIKEN

**Inventor's  
Signature**

**Date**

**Residence: City**

Palos Verdes Estates

**State**

CA

**Country**

USA

**Citizenship**

USA

**Post Office Address**

2007 Via Visalia

**Post Office Address**

**City**

Palos Verdes Estates

**State**

CA

**ZIP**

90274

**Country**

USA

**Name of Additional Joint Inventor, if any:**

☐ A petition has been filed for this unsigned inventor

Given Name (first and middle [if any])

Family Name or Surname

**Inventor's  
Signature**

**Date**

**Residence: City**

**State**

**Country**

**Citizenship**

**Post Office Address**

**Post Office Address**

**City**

**State**

**ZIP**

**Country**

Burden Hour Statement: This form is estimated to take 0.4 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.